An apparently leaked memo from the Biotechnology Innovation Organization (BIO), an industry association, is causing a stir: It suggests that the association, whose members include pharmaceutical companies such as Pfizer, Merck, Novavax and Vaxcyte, is planning a targeted campaign to unseat Robert F. Kennedy Jr., the U.S. Secretary of Health and Human Services. A document published by the Brownstone Institute, titled “The Plot to Get RFK,” outlines a strategy that is seen as an attack on regulatory reform and democratic integrity.
Go straight to the video with German subtitles:
Background to the leaked document
Internal minutes of BIO’s vaccine policy steering committee were allegedly leaked by whistleblowers to the Popular Rationalism platform and document a meeting where plans were made to neutralize Kennedy’s influence. The document has not yet been publicly confirmed, and the statements it contains reflect BIO’s internal strategy. Readers are encouraged to seek independent verification and to critically review the information.
Strategic fraud and financial interests
According to the protocol, BIO allocated $2 million—half of its cash reserves—to a campaign that portrayed Kennedy as a threat to the interests of the biotech industry. This campaign, disguised as a public relations initiative called “Why We Vaccinate,” is not aimed at education but at influencing behavior. Emotional messages that link fear to issues such as national security, economic productivity, and the workforce are designed to manipulate public opinion and lawmakers.
The document reveals a multi-faceted strategy to deceive, silence dissent, and protect industry interests through influence operations. BIO plans to use agents across the political spectrum, including Dr. Mehmet Oz, former Senator Richard Burr, and the American Enterprise Institute (AEI), to undermine Kennedy’s reforms without directly confronting his criticisms.
Fear of regulatory liability
The BIO campaign appears to be motivated less by science and more by fear of regulatory scrutiny that could threaten the industry’s profitable business model. Kennedy’s reform agenda, which calls for stricter standards for post-market surveillance of vaccines, is perceived as a systemic disruption. According to the minutes, one meeting participant expressed concern that investors would hesitate because of Kennedy’s “unpredictability” that would jeopardize the vaccine industry’s capital channels.
The memorandum suggests that BIO uses terms like “efficiency” and “resilience” to cover up lower safety standards and consumer compliance rather than promote real reform or transparency. The organization plans to dominate public debate with authoritative voices without directly challenging Kennedy’s arguments.
Controversies over vaccines and autism
The leak is further compounded by a recent interview RFK Jr. did with Tucker Carlson. In it, Kennedy discussed a covert 1999 study that allegedly showed a worrying increase in autism risk from the hepatitis B vaccine. He pointed out that many pediatricians are financially dependent on vaccinations, which account for up to 50% of their income. He also criticized the fact that the link between vaccines in the first six months of life and autism has never been tested and that the CDC has eliminated an effective reporting system for vaccine side effects because it “worked too well.”
An attack on transparency?
The leaked protocol is seen as part of a larger pattern aimed at suppressing transparency and dissent. It joins other mechanisms, such as ESG-based financial leverage or algorithmic censorship on social media. Critics see it not as a fight against disinformation, but rather as a “war on scientific transparency.” The BIO campaign is seen as a desperate attempt to buy time before the public demands greater accountability.
Summary
An apparently leaked memo sheds light on the biotech industry’s strategies to thwart regulatory reform and protect its financial interests. It raises the question of whether science regulation should serve the public or shareholders. The revelations call on the public to examine the evidence and initiate a debate about transparency and accountability in the healthcare industry. Further developments on this issue remain to be seen, but the document has already sparked debate about the integrity of democratic processes and the role of lobbying groups.
